Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan
•From March to November 2021, homologous or heterologous regimens with ChAdOx1-S and mRNA-1273 vaccination (ChAdOx1-S/ChAdOx1-S, mRNA-1273/mRNA-1273, ChAdOx1-S/mRNA-1273) were given to 945 healthy participants.•Heterologous vaccination with ChAdOx1-S/mRNA-1273 had an acceptable safety profile and in...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical virology 2022-06, Vol.150-151, p.105156-105156, Article 105156 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 105156 |
|---|---|
| container_issue | |
| container_start_page | 105156 |
| container_title | Journal of clinical virology |
| container_volume | 150-151 |
| creator | Kang, Chun-Min Lee, Nan-Yao Lin, Chih-Hsueh Hsu, Yuan-Shan Chang, Yu-Chang Chung, Ming-Yi Lee, Ya-Fan Tseng, Wen-Pin Wu, Jhong-Lin Chen, Shey-Ying Lu, Min-Chi Ko, Wen-Chien Lee, Ping-Ing Hsueh, Po-Ren |
| description | •From March to November 2021, homologous or heterologous regimens with ChAdOx1-S and mRNA-1273 vaccination (ChAdOx1-S/ChAdOx1-S, mRNA-1273/mRNA-1273, ChAdOx1-S/mRNA-1273) were given to 945 healthy participants.•Heterologous vaccination with ChAdOx1-S/mRNA-1273 had an acceptable safety profile and induced higher total anti-RBD/S1 antibody production (p |
| doi_str_mv | 10.1016/j.jcv.2022.105156 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8986279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1386653222000890</els_id><sourcerecordid>2649998130</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-e738ac450ca744f444fffc33602bdb0d87ab87e56ceaadf1d2fe08307e10099e3</originalsourceid><addsrcrecordid>eNp9UUtr3DAQFqWhSdP-gF6Kj714K1nWwxQKy9JHIDSQpGehlUZrLbaUWvK2---r7CahveQgNDPfQ2I-hN4RvCCY8I_bxdbsFg1umtIzwvgLdEakoDXruHhZaip5zRltTtHrlLYYE0Zb8QqdUtYSyqQ8Q_uLcZxD3EDwxud9pYOtknZQyuiqPo5xiJs4pwPQQ4bpcbDql_bqD6lvDtB4_WNZk0bQaqeN8UFnH0OqfCgiPeS-ONt5yIfJrfa_dXiDTpweErx9uM_Rz69fblff68urbxer5WVtWkZyDYJKXUpstGhb15bjnKGU42Zt19hKoddSAOMGtLaO2MYBlhQLIBh3HdBz9PnoezevR7AGQp70oO4mP-ppr6L26n8k-F5t4k7JTvJGdMXgw4PBFH_NkLIafTIwDDpAWYRqeNt1nSQUFyo5Us0UU5rAPT1DsLqPTG1ViUzdR6aOkRXN-3__96R4zKgQPh0JULa08zCpZDwEA9ZPYLKy0T9j_xcM0alH</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2649998130</pqid></control><display><type>article</type><title>Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kang, Chun-Min ; Lee, Nan-Yao ; Lin, Chih-Hsueh ; Hsu, Yuan-Shan ; Chang, Yu-Chang ; Chung, Ming-Yi ; Lee, Ya-Fan ; Tseng, Wen-Pin ; Wu, Jhong-Lin ; Chen, Shey-Ying ; Lu, Min-Chi ; Ko, Wen-Chien ; Lee, Ping-Ing ; Hsueh, Po-Ren</creator><creatorcontrib>Kang, Chun-Min ; Lee, Nan-Yao ; Lin, Chih-Hsueh ; Hsu, Yuan-Shan ; Chang, Yu-Chang ; Chung, Ming-Yi ; Lee, Ya-Fan ; Tseng, Wen-Pin ; Wu, Jhong-Lin ; Chen, Shey-Ying ; Lu, Min-Chi ; Ko, Wen-Chien ; Lee, Ping-Ing ; Hsueh, Po-Ren</creatorcontrib><description>•From March to November 2021, homologous or heterologous regimens with ChAdOx1-S and mRNA-1273 vaccination (ChAdOx1-S/ChAdOx1-S, mRNA-1273/mRNA-1273, ChAdOx1-S/mRNA-1273) were given to 945 healthy participants.•Heterologous vaccination with ChAdOx1-S/mRNA-1273 had an acceptable safety profile and induced higher total anti-RBD/S1 antibody production (p < 0.0001), yet lower anti-RBD/S1 IgG titer (p < 0.0001) and neutralizing ability (p = 0.0101) than mRNA-1273/mRNA-1273 group.•Both regimens showed higher antibody titers and superior neutralizing abilities than ChAdOx1-S/ChAdOx1-S.•Heterologous ChAdOx1-S/mRNA-1273 vaccination regimen is generally safe and induces a robust humoral immune response that is non-inferior to that of mRNA-1273/mRNA-1273.
: In Taiwan, the vaccination program started in March 2021, with ChAdOx1-S being the first available WHO-approved COVID-19 vaccine, followed by Moderna vaccine. This study aimed to investigate the immunogenicity and safety of homologous and heterologous prime-boost regimens with ChAdOx1-S and mRNA-1273.
: From March to November 2021, homologous or heterologous regimens with ChAdOx1-S and mRNA-1273 vaccination (ChAdOx1-S/ChAdOx1-S, mRNA-1273/mRNA-1273, ChAdOx1-S/mRNA-1273) were given to 945 healthy participants. Serum samples were collected at designated time points. The anti-RBD/S1 antibody titers and neutralizing ability were measured by three different immunoassays: Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics, Mannheim, Germany), AdviseDx SARS-CoV-2 IgG II (Abbott Diagnostics Division, Sligo, Ireland), and cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript, New Jersey, USA).
: We found that heterologous vaccination with ChAdOx1-S/mRNA-1273 had an acceptable safety profile and induced higher total anti-RBD/S1 antibody production (p < 0.0001), yet lower anti-RBD/S1 IgG titer (p < 0.0001) and neutralizing ability (p = 0.0101) than mRNA-1273/mRNA-1273 group. Both regimens showed higher antibody titers and superior neutralizing abilities than ChAdOx1-S/ChAdOx1-S. An age-dependent antibody response to ChAdOx1-S/mRNA-1273 was shown after both the priming and the booster doses. Younger age was associated with higher antibody production and neutralizing ability.
: Heterologous ChAdOx1-S/mRNA-1273 vaccination regimen is generally safe and induces a robust humoral immune response that is non-inferior to that of mRNA-1273/mRNA-1273.</description><identifier>ISSN: 1386-6532</identifier><identifier>ISSN: 1873-5967</identifier><identifier>EISSN: 1873-5967</identifier><identifier>DOI: 10.1016/j.jcv.2022.105156</identifier><identifier>PMID: 35413588</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>2019-nCoV Vaccine mRNA-1273 - adverse effects ; 2019-nCoV Vaccine mRNA-1273 - immunology ; Adult ; Antibodies, Viral ; ChAdOx1 nCoV-19 - adverse effects ; ChAdOx1 nCoV-19 - immunology ; COVID-19 - prevention & control ; COVID-19 vaccines ; Homologous and heterologous prime-boost regimens ; Humans ; Immunogenicity ; Immunogenicity, Vaccine ; Immunoglobulin G ; Safety ; SARS-CoV-2 ; Taiwan ; Vaccination</subject><ispartof>Journal of clinical virology, 2022-06, Vol.150-151, p.105156-105156, Article 105156</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><rights>2022 Elsevier B.V. All rights reserved. 2022 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-e738ac450ca744f444fffc33602bdb0d87ab87e56ceaadf1d2fe08307e10099e3</citedby><cites>FETCH-LOGICAL-c451t-e738ac450ca744f444fffc33602bdb0d87ab87e56ceaadf1d2fe08307e10099e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1386653222000890$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35413588$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kang, Chun-Min</creatorcontrib><creatorcontrib>Lee, Nan-Yao</creatorcontrib><creatorcontrib>Lin, Chih-Hsueh</creatorcontrib><creatorcontrib>Hsu, Yuan-Shan</creatorcontrib><creatorcontrib>Chang, Yu-Chang</creatorcontrib><creatorcontrib>Chung, Ming-Yi</creatorcontrib><creatorcontrib>Lee, Ya-Fan</creatorcontrib><creatorcontrib>Tseng, Wen-Pin</creatorcontrib><creatorcontrib>Wu, Jhong-Lin</creatorcontrib><creatorcontrib>Chen, Shey-Ying</creatorcontrib><creatorcontrib>Lu, Min-Chi</creatorcontrib><creatorcontrib>Ko, Wen-Chien</creatorcontrib><creatorcontrib>Lee, Ping-Ing</creatorcontrib><creatorcontrib>Hsueh, Po-Ren</creatorcontrib><title>Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan</title><title>Journal of clinical virology</title><addtitle>J Clin Virol</addtitle><description>•From March to November 2021, homologous or heterologous regimens with ChAdOx1-S and mRNA-1273 vaccination (ChAdOx1-S/ChAdOx1-S, mRNA-1273/mRNA-1273, ChAdOx1-S/mRNA-1273) were given to 945 healthy participants.•Heterologous vaccination with ChAdOx1-S/mRNA-1273 had an acceptable safety profile and induced higher total anti-RBD/S1 antibody production (p < 0.0001), yet lower anti-RBD/S1 IgG titer (p < 0.0001) and neutralizing ability (p = 0.0101) than mRNA-1273/mRNA-1273 group.•Both regimens showed higher antibody titers and superior neutralizing abilities than ChAdOx1-S/ChAdOx1-S.•Heterologous ChAdOx1-S/mRNA-1273 vaccination regimen is generally safe and induces a robust humoral immune response that is non-inferior to that of mRNA-1273/mRNA-1273.
: In Taiwan, the vaccination program started in March 2021, with ChAdOx1-S being the first available WHO-approved COVID-19 vaccine, followed by Moderna vaccine. This study aimed to investigate the immunogenicity and safety of homologous and heterologous prime-boost regimens with ChAdOx1-S and mRNA-1273.
: From March to November 2021, homologous or heterologous regimens with ChAdOx1-S and mRNA-1273 vaccination (ChAdOx1-S/ChAdOx1-S, mRNA-1273/mRNA-1273, ChAdOx1-S/mRNA-1273) were given to 945 healthy participants. Serum samples were collected at designated time points. The anti-RBD/S1 antibody titers and neutralizing ability were measured by three different immunoassays: Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics, Mannheim, Germany), AdviseDx SARS-CoV-2 IgG II (Abbott Diagnostics Division, Sligo, Ireland), and cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript, New Jersey, USA).
: We found that heterologous vaccination with ChAdOx1-S/mRNA-1273 had an acceptable safety profile and induced higher total anti-RBD/S1 antibody production (p < 0.0001), yet lower anti-RBD/S1 IgG titer (p < 0.0001) and neutralizing ability (p = 0.0101) than mRNA-1273/mRNA-1273 group. Both regimens showed higher antibody titers and superior neutralizing abilities than ChAdOx1-S/ChAdOx1-S. An age-dependent antibody response to ChAdOx1-S/mRNA-1273 was shown after both the priming and the booster doses. Younger age was associated with higher antibody production and neutralizing ability.
: Heterologous ChAdOx1-S/mRNA-1273 vaccination regimen is generally safe and induces a robust humoral immune response that is non-inferior to that of mRNA-1273/mRNA-1273.</description><subject>2019-nCoV Vaccine mRNA-1273 - adverse effects</subject><subject>2019-nCoV Vaccine mRNA-1273 - immunology</subject><subject>Adult</subject><subject>Antibodies, Viral</subject><subject>ChAdOx1 nCoV-19 - adverse effects</subject><subject>ChAdOx1 nCoV-19 - immunology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 vaccines</subject><subject>Homologous and heterologous prime-boost regimens</subject><subject>Humans</subject><subject>Immunogenicity</subject><subject>Immunogenicity, Vaccine</subject><subject>Immunoglobulin G</subject><subject>Safety</subject><subject>SARS-CoV-2</subject><subject>Taiwan</subject><subject>Vaccination</subject><issn>1386-6532</issn><issn>1873-5967</issn><issn>1873-5967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UUtr3DAQFqWhSdP-gF6Kj714K1nWwxQKy9JHIDSQpGehlUZrLbaUWvK2---r7CahveQgNDPfQ2I-hN4RvCCY8I_bxdbsFg1umtIzwvgLdEakoDXruHhZaip5zRltTtHrlLYYE0Zb8QqdUtYSyqQ8Q_uLcZxD3EDwxud9pYOtknZQyuiqPo5xiJs4pwPQQ4bpcbDql_bqD6lvDtB4_WNZk0bQaqeN8UFnH0OqfCgiPeS-ONt5yIfJrfa_dXiDTpweErx9uM_Rz69fblff68urbxer5WVtWkZyDYJKXUpstGhb15bjnKGU42Zt19hKoddSAOMGtLaO2MYBlhQLIBh3HdBz9PnoezevR7AGQp70oO4mP-ppr6L26n8k-F5t4k7JTvJGdMXgw4PBFH_NkLIafTIwDDpAWYRqeNt1nSQUFyo5Us0UU5rAPT1DsLqPTG1ViUzdR6aOkRXN-3__96R4zKgQPh0JULa08zCpZDwEA9ZPYLKy0T9j_xcM0alH</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Kang, Chun-Min</creator><creator>Lee, Nan-Yao</creator><creator>Lin, Chih-Hsueh</creator><creator>Hsu, Yuan-Shan</creator><creator>Chang, Yu-Chang</creator><creator>Chung, Ming-Yi</creator><creator>Lee, Ya-Fan</creator><creator>Tseng, Wen-Pin</creator><creator>Wu, Jhong-Lin</creator><creator>Chen, Shey-Ying</creator><creator>Lu, Min-Chi</creator><creator>Ko, Wen-Chien</creator><creator>Lee, Ping-Ing</creator><creator>Hsueh, Po-Ren</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220601</creationdate><title>Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan</title><author>Kang, Chun-Min ; Lee, Nan-Yao ; Lin, Chih-Hsueh ; Hsu, Yuan-Shan ; Chang, Yu-Chang ; Chung, Ming-Yi ; Lee, Ya-Fan ; Tseng, Wen-Pin ; Wu, Jhong-Lin ; Chen, Shey-Ying ; Lu, Min-Chi ; Ko, Wen-Chien ; Lee, Ping-Ing ; Hsueh, Po-Ren</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-e738ac450ca744f444fffc33602bdb0d87ab87e56ceaadf1d2fe08307e10099e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>2019-nCoV Vaccine mRNA-1273 - adverse effects</topic><topic>2019-nCoV Vaccine mRNA-1273 - immunology</topic><topic>Adult</topic><topic>Antibodies, Viral</topic><topic>ChAdOx1 nCoV-19 - adverse effects</topic><topic>ChAdOx1 nCoV-19 - immunology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 vaccines</topic><topic>Homologous and heterologous prime-boost regimens</topic><topic>Humans</topic><topic>Immunogenicity</topic><topic>Immunogenicity, Vaccine</topic><topic>Immunoglobulin G</topic><topic>Safety</topic><topic>SARS-CoV-2</topic><topic>Taiwan</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Chun-Min</creatorcontrib><creatorcontrib>Lee, Nan-Yao</creatorcontrib><creatorcontrib>Lin, Chih-Hsueh</creatorcontrib><creatorcontrib>Hsu, Yuan-Shan</creatorcontrib><creatorcontrib>Chang, Yu-Chang</creatorcontrib><creatorcontrib>Chung, Ming-Yi</creatorcontrib><creatorcontrib>Lee, Ya-Fan</creatorcontrib><creatorcontrib>Tseng, Wen-Pin</creatorcontrib><creatorcontrib>Wu, Jhong-Lin</creatorcontrib><creatorcontrib>Chen, Shey-Ying</creatorcontrib><creatorcontrib>Lu, Min-Chi</creatorcontrib><creatorcontrib>Ko, Wen-Chien</creatorcontrib><creatorcontrib>Lee, Ping-Ing</creatorcontrib><creatorcontrib>Hsueh, Po-Ren</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Chun-Min</au><au>Lee, Nan-Yao</au><au>Lin, Chih-Hsueh</au><au>Hsu, Yuan-Shan</au><au>Chang, Yu-Chang</au><au>Chung, Ming-Yi</au><au>Lee, Ya-Fan</au><au>Tseng, Wen-Pin</au><au>Wu, Jhong-Lin</au><au>Chen, Shey-Ying</au><au>Lu, Min-Chi</au><au>Ko, Wen-Chien</au><au>Lee, Ping-Ing</au><au>Hsueh, Po-Ren</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan</atitle><jtitle>Journal of clinical virology</jtitle><addtitle>J Clin Virol</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>150-151</volume><spage>105156</spage><epage>105156</epage><pages>105156-105156</pages><artnum>105156</artnum><issn>1386-6532</issn><issn>1873-5967</issn><eissn>1873-5967</eissn><abstract>•From March to November 2021, homologous or heterologous regimens with ChAdOx1-S and mRNA-1273 vaccination (ChAdOx1-S/ChAdOx1-S, mRNA-1273/mRNA-1273, ChAdOx1-S/mRNA-1273) were given to 945 healthy participants.•Heterologous vaccination with ChAdOx1-S/mRNA-1273 had an acceptable safety profile and induced higher total anti-RBD/S1 antibody production (p < 0.0001), yet lower anti-RBD/S1 IgG titer (p < 0.0001) and neutralizing ability (p = 0.0101) than mRNA-1273/mRNA-1273 group.•Both regimens showed higher antibody titers and superior neutralizing abilities than ChAdOx1-S/ChAdOx1-S.•Heterologous ChAdOx1-S/mRNA-1273 vaccination regimen is generally safe and induces a robust humoral immune response that is non-inferior to that of mRNA-1273/mRNA-1273.
: In Taiwan, the vaccination program started in March 2021, with ChAdOx1-S being the first available WHO-approved COVID-19 vaccine, followed by Moderna vaccine. This study aimed to investigate the immunogenicity and safety of homologous and heterologous prime-boost regimens with ChAdOx1-S and mRNA-1273.
: From March to November 2021, homologous or heterologous regimens with ChAdOx1-S and mRNA-1273 vaccination (ChAdOx1-S/ChAdOx1-S, mRNA-1273/mRNA-1273, ChAdOx1-S/mRNA-1273) were given to 945 healthy participants. Serum samples were collected at designated time points. The anti-RBD/S1 antibody titers and neutralizing ability were measured by three different immunoassays: Elecsys® Anti-SARS-CoV-2 S (Roche Diagnostics, Mannheim, Germany), AdviseDx SARS-CoV-2 IgG II (Abbott Diagnostics Division, Sligo, Ireland), and cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript, New Jersey, USA).
: We found that heterologous vaccination with ChAdOx1-S/mRNA-1273 had an acceptable safety profile and induced higher total anti-RBD/S1 antibody production (p < 0.0001), yet lower anti-RBD/S1 IgG titer (p < 0.0001) and neutralizing ability (p = 0.0101) than mRNA-1273/mRNA-1273 group. Both regimens showed higher antibody titers and superior neutralizing abilities than ChAdOx1-S/ChAdOx1-S. An age-dependent antibody response to ChAdOx1-S/mRNA-1273 was shown after both the priming and the booster doses. Younger age was associated with higher antibody production and neutralizing ability.
: Heterologous ChAdOx1-S/mRNA-1273 vaccination regimen is generally safe and induces a robust humoral immune response that is non-inferior to that of mRNA-1273/mRNA-1273.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35413588</pmid><doi>10.1016/j.jcv.2022.105156</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6532 |
| ispartof | Journal of clinical virology, 2022-06, Vol.150-151, p.105156-105156, Article 105156 |
| issn | 1386-6532 1873-5967 1873-5967 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8986279 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | 2019-nCoV Vaccine mRNA-1273 - adverse effects 2019-nCoV Vaccine mRNA-1273 - immunology Adult Antibodies, Viral ChAdOx1 nCoV-19 - adverse effects ChAdOx1 nCoV-19 - immunology COVID-19 - prevention & control COVID-19 vaccines Homologous and heterologous prime-boost regimens Humans Immunogenicity Immunogenicity, Vaccine Immunoglobulin G Safety SARS-CoV-2 Taiwan Vaccination |
| title | Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T23%3A15%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20and%20safety%20of%20homologous%20and%20heterologous%20ChAdOx1-S%20and%20mRNA-1273%20vaccinations%20in%20healthy%20adults%20in%20Taiwan&rft.jtitle=Journal%20of%20clinical%20virology&rft.au=Kang,%20Chun-Min&rft.date=2022-06-01&rft.volume=150-151&rft.spage=105156&rft.epage=105156&rft.pages=105156-105156&rft.artnum=105156&rft.issn=1386-6532&rft.eissn=1873-5967&rft_id=info:doi/10.1016/j.jcv.2022.105156&rft_dat=%3Cproquest_pubme%3E2649998130%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2649998130&rft_id=info:pmid/35413588&rft_els_id=S1386653222000890&rfr_iscdi=true |